These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8813234)

  • 1. Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy.
    Shan DE; Kwan SY; Ho HH; Su MS
    Mov Disord; 1996 Jul; 11(4):455-7. PubMed ID: 8813234
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 4. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 8. Case 1, 1996: rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma.
    Fahn S; Brin MF; Dwork AJ; Weiner WJ; Goetz CG; Rajput AH
    Mov Disord; 1996 May; 11(3):298-310. PubMed ID: 8723148
    [No Abstract]   [Full Text] [Related]  

  • 9. Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
    Pouclet H; Derkinderen P; Lebouvier T
    Clin Neurol Neurosurg; 2013 Feb; 115(2):235-6. PubMed ID: 22743235
    [No Abstract]   [Full Text] [Related]  

  • 10. Dystonia and Parkinson's disease.
    Carella F; Giovannini P; Girotti F; Testa D; Caraceni T
    Adv Neurol; 1993; 60():558-61. PubMed ID: 8420191
    [No Abstract]   [Full Text] [Related]  

  • 11. Anticholinergics and dyskinesia.
    Linazasoro G
    Mov Disord; 1994 Nov; 9(6):689. PubMed ID: 7845412
    [No Abstract]   [Full Text] [Related]  

  • 12. Amantadine-induced "vocal" myoclonus.
    Pfeiffer RF
    Mov Disord; 1996 Jan; 11(1):104-6. PubMed ID: 8771080
    [No Abstract]   [Full Text] [Related]  

  • 13. A family with hereditary juvenile dystonia-parkinsonism.
    Ishikawa A; Miyatake T
    Mov Disord; 1995 Jul; 10(4):482-8. PubMed ID: 7565830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).
    Lew MF; Shindo M; Moskowitz CB; Wilhelmsen KC; Fahn S; Waters CH
    Mov Disord; 1994 May; 9(3):318-20. PubMed ID: 8041372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zotepine in levodopa-induced Psychosis.
    Spieker S; Stetter F; Klockgether T
    Mov Disord; 1995 Nov; 10(6):795-7. PubMed ID: 8750001
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 18. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 19. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Coyle J; Hobson P; Meara J
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
    [No Abstract]   [Full Text] [Related]  

  • 20. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Heinonen E; Myllylä V
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.